Somaxon Pharmaceuticals — Investor Presentation (November 2006)
36 slides from Somaxon Pharmaceuticals's investor presentation, Nov 28, 2006
Slide 1: Specialty Pharmaceuticals for Psychiatry & Neurology
Specialty Pharmaceuticals for Psychiatry & Neurology NASDAQ: SOMX
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements about our business, including results of our clinical trials, potential indications for our product candidates, development timelines, future financial results and events that have not yet occurred. Pharmaceutical devel
Slide 3: Highlights
Highlights Specialty pharmaceuticals focused on psychiatric and neurologic disorders Three in-licensed product candidates with extensive human experience & established safety records Highly differentiated product profiles addressing large markets, including 3 positive Phase 3 trials in insomnia Comp
Slide 4: Pipeline
Pipeline SILENOR(tm) - Insomnia Nalmefene - Impulse Control Disorders Acamprosate Movement Disorders Pre- Clinical Phase 1 Phase 2 Phase 3 Nalmefene - Smoking Cessation
Slide 5: Insomnia Market Growth
Insomnia Market Growth 2001 2002 2003 2004 2005 East 1.3 1.8 2.2 2.7 3.3 Total Dollars Billions $1.3 $1.8 $2.2 $2.7 $3.3 Source: Wolters Kluwer Health
Slide 6: Insomnia Prescription Growth
Insomnia Prescription Growth 2001 2002 2003 2004 2005 Ambien 14.89 19.33 22.14 24.49 24.8 Trazodone 8.43 9.5 10.15 10.84 10.81 Other 5.25 5.66 6.01 6.36 6.47 Sonata 1.56 1.78 1.68 1.58 1.38 Lunesta 0 0 0 0 3.18 Ambien CR 0 0 0 0 0.62 Rozerem 0 0 0 0 0.13 Total Rx Millions 30 36 40 43 47 Source: Wolt
Slide 7: Insomnia Market Growth
Insomnia Market Growth S an Insomnia Drug TRx 13wk MA 950,000 900,000 850,000 200,000 Negative Ambien 750,000 press begins 700,000 650,000 Ambion CR launch 600,000 e 2 e F F& & » SS CG KM e re ns ‘Source: IMS Health
Slide 8: Insomnia Complaints
Insomnia Complaints 70 Million Americans report symptoms of insomnia Somaxon estimates fewer than 10 Million use Rx treatment Sleep in America Poll 2002 Difficulty falling asleep Waking frequently during the night Waking too early Wake feeling unrefreshed 25% 40% 24% 36% Sleep Maintenance 24% 36%
Slide 9: Lunesta Schedule IV controlled substance warning
LUNESTA has been classified as a Schedule IV controlled substance. Sedative hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. The risk of abuse and dependence increases with the dose and duration of treatment Lunesta
Slide 10: SILENOR (doxepin HCl) for Insomnia
SILENOR(tm)(doxepin HCl) for Insomnia Tricyclic compound approved >35 years as an antidepressant Long term safety record with chronic usage A range of pharmacologic activities at high dosages, while clinically a selective H1 antagonist at very low dosages Believed to promote sleep via H1, not GABA
Slide 11: SILENOR vs GABA acting drugs
"Doxepin HCl is virtually devoid of euphoria as a side effect. Characteristic of this type of compound, doxepin HCl has not been demonstrated to produce the physical tolerance or psychological dependence associated with addictive compounds." SILENOR(tm) vs GABA acting drugs "LUNESTA is a Schedule IV
Slide 12: Daily Dosage and patents
Daily Dosage (mg) 10 25 50 75 300 Depression Sedation, anticholinergic & other side effects Two issued US patents claiming treatment of insomnia at low dose Additional patent applications on file/in process 1 6 Insomnia SILENOR(tm) Well tolerated 3
Slide 13: Product Differentiation
Product Differentiation Doxepin HCl Silenor(tm) Available Dosage Forms 10-150mg 1,3, (6)mg Product Form Capsules Tablets Indication Depression Insomnia Anticholinergic Yes No Daytime Sedation Yes No Branded/Promoted No Yes Sampled No Yes Patents No Yes Hatch-Waxman Exclusivity No Yes
Slide 14: Chronic Insomnia PSG Trial: Wake After Sleep Onset
PBO DXP 3mg DXP 6mg N1 66.7 41.4 36.3 N29 61.8 47.3 41.2 Minutes (mean) Nights p<0.0001 p<0.0001 p=0.0299 p=0.0012 Wake After Sleep Onset (WASO) Phase 3 - Chronic Insomnia PSG Trial Primary Endpoint
Slide 15: Chronic Insomnia PSG Trial: Total Sleep Time
PBO DXP 3mg DXP 6mg N1 373.8 415.3 420.5 N29 391 408.1 419.1 Nights p<0.0001 p<0.0001 p=0.0262 p=0.0003 Phase 3 - Chronic Insomnia PSG Trial Total Sleep Time (TST) Minutes (mean)
Slide 16: Chronic Insomnia PSG Trial: Latency to Persistent Sleep
PBO DXP 3mg DXP 6mg N1 45 26.7 27.1 N29 31.3 28 24.7 Nights Phase 3 - Chronic Insomnia PSG Trial Latency to Persistent Sleep (LPS) p=0.0018 p=0.0110 p=0.9008 p=0.9989 Minutes (mean)
Slide 17: Chronic Insomnia PSG Trial: Sleep Efficiency by Hour
PBO DXP 3mg DXP 6mg 0 1 0.505 0.62 0.606 2 0.783 0.901 0.914 3 0.848 0.933 0.93 4 0.861 0.909 0.932 5 0.829 0.898 0.901 6 0.807 0.894 0.93 7 0.852 0.888 0.912 8 0.745 0.878 0.884 Phase 3 - Chronic Insomnia PSG Trial Sleep Efficiency (SE) - by Hour Night 1
Slide 18: Transient Insomnia PSG Trial
Objectives Efficacy on sleep onset and sleep duration Design - Phase 3, randomized, controlled, double blind, multicenter, parallel group, sleep laboratory Population - Transient insomnia population using first night effect plus phase advance model in healthy volunteers Dose - Placebo and 6 mg Endpo
Slide 19: Transient Insomnia: Latency to Persistent Sleep
PBO 33.6 DXP 6mg 20.6 Phase 3 - Transient Insomnia PSG Trial Primary Endpoint P<0.0001 Latency to Persistent Sleep (LPS) Minutes (mean)
Slide 20: Transient Insomnia: Latency to Sleep Onset
PBO 48 DXP 6mg 32 Phase 3 - Transient Insomnia PSG Trial Latency to Sleep Onset (LSO) Minutes (mean) P<0.0001
Slide 21: Transient Insomnia: Wake After Sleep Onset
PBO 78 DXP 6mg 38 Phase 3 - Transient Insomnia PSG Trial Wake After Sleep Onset (WASO) Minutes (mean) P<0.0001
Slide 22: Transient Insomnia: Total Sleep Time
PBO 374 DXP 6mg 425 Phase 3 - Transient Insomnia PSG Trial Total Sleep Time (TST) Minutes (mean) P<0.0001
Slide 23: Transient Insomnia: Subjective Measures
Placebo (N=282) Doxepin 6 mg (N=283) sTST Mean (SD): 394.1 (78.2) 427.2 (47.5) p-value: <0.0001 sWASO Mean (SD): 36.6 (44.4) 26.0 (50.2) p-value: 0.0063 Sleep Quality1 Mean (SD): 0.8 (1.25) 1.2 (1.01) p-value: 0.0004 Phase 3 - Transient Insomnia PSG Trial Subjective Measures 1 7-point Likert scale r
Slide 24: Elderly Insomnia Trial
Phase 3 - Elderly Insomnia Trial Objectives Efficacy and safety for up to 4 weeks Design - Phase 3, randomized, placebo-controlled, double blind, parallel group, multicenter, outpatient study Population - Elderly Patients with DSM IV Primary SM insomnia Dose - Placebo and 6 mg Endpoints Primary -Sub
Slide 25: Elderly Insomnia: Primary Endpoint sTST
PBO DXP 6mg Baseline 0 0 Week 1 23.2 52.1 Week 2 34.7 49.2 Week 3 38.2 58.3 Week 4 42.9 63 <0.0001 0.0017 Minutes (mean) Week of study Phase 3 - Elderly Insomnia Trial Primary Endpoint sTST Change from Mean Baseline
Slide 26: Elderly Insomnia: sWASO Change from Baseline
PBO DXP 6mg Baseline 0 0 Week 1 -14.6 -37.4 Week 2 -26.9 -40.6 Week 3 -29.6 -46.1 Week 4 -33.1 -50 0.0026 <0.0001 Minutes (mean) Week of study Phase 3 - Elderly Insomnia Trial sWASO Change from Mean Baseline
Slide 27: Elderly Insomnia: LSO Change from Baseline
PBO DXP 6mg Baseline 0 0 Week 1 -9.3 -18.1 Week 2 -18.3 -15.4 Week 3 -16.6 -19.8 Week 4 -19.8 -21.9 0.1547 0.6629 Minutes (mean) Week of study Phase 3 - Elderly Insomnia Trial LSO Change from Mean Baseline
Slide 28: Elderly Insomnia: Sleep Onset, Maintenance, Duration
6 mg sTST 6 mg LSO 6 mg sWASO Baseline 0 0 0 Week 1 52.1 -18.1 -37.4 Week 4 63 -21.9 -50 Phase 3 - Elderly Insomnia Trial Sleep Onset, Maintenance, Duration (ITT) Change from Mean Baseline Minutes (mean) sTST LSO sWASO Week of study
Slide 29: Safety & Tolerability
Phase 3 Trials to Date Safety & Tolerability Well tolerated Overall AE incidence comparable to placebo Low discontinuation rate No clinically meaningful next day effects No rebound insomnia, withdrawal effects or tolerance No amnesia or weight gain observed
Slide 30: Positioning
Positioning Targeted by Phase 3 Amnesia Euphoria Hormone Changes Metallic Taste Attributes Sonata Ambien Ambien CR Lunesta Indiplon Rozerem SILENORTM Onset Maintenance ? Last 3rd of Night Long Term Studies ? Not Scheduled Not GABA
Slide 31: SILENOR Development Plan
SILENOR(tm) Development Plan Ph 3 Transient 2005 2006 2007 Ph 3 Adult PSG Ph 1 PK Studies Ph 3 Elderly PSG Ph 3 Elderly Outpatient Submit NDA Pre-Clinical
Slide 32: Nalmefene
Nalmefene Opioid receptor antagonist, marketed in IV form since 1995 for opiate reversal Somaxon product is orally administered Opioid antagonism can reduce urges & cravings
Slide 33: Nalmefene Clinical Development Plan
Ph 2/3 Pathological Gambling Clinical Development Plan TBD 2005 2006 2007 2008 2009 Ph 2 Smoking Pilot
Slide 34: Financial Highlights, 9/30/06
Financial Highlights, 9/30/06 NASDAQ: SOMX Cash, cash equivalents & short term investments Cash burn, YTD 9-30-06 Shares outstanding Fully diluted shares $67.1 mm $37.0 mm 18.1 mm 20.5 mm
Slide 35: Key milestones
Key milestones SILENOR(tm) Phase 3 adult results - Q2 '06 ^ Phase 3 transient results - late '06 ^ Phase 3 elderly 4 wk outpatient results - Nov. '06 ^ Phase 3 elderly 3 month PSG results - Dec. '06 Strategic partnership NDA - Q3 '07 Nalmefene Pilot smoking cessation results - mid '06 ^ Phase 2/3 PG
Slide 36: Highlights
Highlights Specialty pharmaceuticals focused on psychiatric and neurologic disorders Three in-licensed product candidates with extensive human experience & established safety records Highly differentiated product profiles addressing large markets, including 3 positive Phase 3 trials in insomnia Comp
Somaxon Pharmaceuticals — Investor Presentation (November 2006) on 6ix